Entera Bio Ltd. Banner Image

Entera Bio Ltd. has reached its limit for free report views

Work for Entera Bio Ltd.? Upgrade Your Profile and unlock all your annual reports.

Entera Bio Ltd.

  • Ticker ENTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Entera Bio Ltd. Logo Image
  • 11-50 Employees
  • Based in Jerusalem, Israel
Entera is a leader in the development of orally delivered macromolecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company’s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variabilityMore, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc.
Entera Bio Ltd.

Most Recent Annual Report

Entera Bio Ltd. MOST RECENT 2019 Annual Report

Report Locked. Entera Bio Ltd. has reached its limit for free report views.

Older/Archived Annual Reports